Alfuzosin

Alfuzosin

File:Alfuzosin.svg
Systematic (IUPAC) name
N-[3-[(4-amino-6,7-dimethoxy-quinazolin-2-yl)- methyl-amino]propyl] tetrahydrofuran- 2-carboxamide
Clinical data
Pregnancy category	AU: B2 US: B (No risk in non-human studies)
Routes of administration	Oral
Legal status
Legal status	UK: POM (Prescription only) US: ℞-only
Pharmacokinetic data
Bioavailability	49%
Protein binding	82%-90%
Metabolism	Hepatic (CYP3A4-mediated)
Biological half-life	10 hours
Excretion	Fecal (69%) and renal (24%)
Identifiers
CAS Number	81403-80-7
ATC code	G04CA01 (WHO)
PubChem	CID 2092
DrugBank	APRD00490
ChemSpider	2008
Chemical data
Formula	C19H27N5O4
Molar mass	389.449 g/mol[[]]
(verify)

Alfuzosin (INN, provided as the hydrochloride salt) is an α₁ receptor antagonist used to treat benign prostatic hyperplasia (BPH). It works by relaxing the muscles in the prostate and bladder neck, making it easier to urinate.

Alfuzosin is marketed in the United States by Sanofi Aventis under the brand name Uroxatral and elsewhere under the tradename Xatral. Alfuzosin was approved by the FDA for treatment of BPH in June 2003.

Side effects

The most common side effects are dizziness (due to postural hypotension), upper respiratory tract infection, headache, and fatigue.

Contraindications

Alfuzosin should be used with caution in patients with severe renal insufficiency, and should not be prescribed to patients with a known history of QT prolongation who are taking medications known to prolong the QT interval.

External links

• Uroxatral (manufacturer's website)
• Alfuzosin (patient information)

fr:Alfuzosine